XCellCure is a startup biotechnology company focused on transforming modern cardiac care by enabling quantitative, low-cost prevention. With the launch of our first product, the AMiAware Human Cardiovascular Disease Microarray, our product line aids the prevention of recurrent heart attack through patient-centered risk stratification utilizing 13 novel biomarkers. The motif of our clinical approach is to noninvasively diagnose and prognosticate patients experiencing acute coronary symptoms in order to assist in patient monitoring, aid therapeutic selection, prevent fatality, and reduce morbidity of cardiovascular disease. We are releasing a collection of cardiac devices for the research, clinical and point of care realms to supplement and improve current care and patient quality of life.
XCellCure’s novel multimarker cardiac panel has application for emergency room personnel to quickly assess the probability of an impending heart attack. The AMiAware product line allows users insight to key clinical evidence through a unique “Signature of Disease” that guides physicians to make accurate and swift decisions, resulting in higher quality of care for patients with acute coronary syndromes. The AMiAware line of devices brings results for 13 known cardiac biomarkers into the diagnostic arsenal of cardiologists in a user-friendly platform giving doctors the decisive power to administer patient-centered therapy more rapidly than ever before.
Our products present the information necessary to prevent a future fatal heart attack and may be used by health care providers evaluating patients at hospitals, labs, physician offices, at the gym, walk in clinics, and emergency rooms across the country. Current detection methods and clinical algorithms cannot predict a heart attack that is likely to happen over the next 24 or 72 hours. This retroactive result verifies at best only that the patient is currently experiencing a heart attack. XCellCure is revolutionizing cardiac diagnostics through an emphasis on prognostics and prevention. With the capability to predict impending heart attack 48 hours to 6 months after patient presentation, the XCellCure AMiAware will give doctors the foresight to predict and stop a heart attack before it has even started.
Not all heart attacks are expressed through classical symptom manifestation. These non-specific symptoms, however, are often heavily relied upon to get a patient to the hospital in the first place. The reliance on generalized symptomatic presentation of Acute Myocardial Infarction is a major cause for sudden cardiac death outside of a hospital especially among patients who have already experienced their first AMI. XCellCure seeks to prevent potentially fatal cardiac events, particularly in patients with cardiac history, as a supplement to generalized symptoms by adding the AMiAware’s “Signature of Disease” to each patient’s clinical picture, giving doctors powerful prognostic utility.
By focusing on preventative medicine with a prognostic “Signature of Disease” approach, technology from XCellCure has the capacity to save hundreds of thousands of U.S. lives and millions of dollars each year.